Krüppel-like factor 9 (KLF9) prevents colorectal cancer through inhibition of interferon-related signaling

Carcinogenesis

Volumn 36, Issue 9, 2015, Pages 946-955

  Brown, Adam R ^a,b   Simmen, Rosalia C M ^a,b   Raj, Vinay R ^b   Van, Trang T ^a   MacLeod, Stewart L ^b   Simmen, Frank A ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; CYTOKINE; FLUOROURACIL; INTERFERON; INTERFERON STIMULATED GENE 15; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 9; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BETA INTERFERON; G1P2 PROTEIN, MOUSE; ISG15 PROTEIN, HUMAN; KLF9 PROTEIN, HUMAN; KLF9 PROTEIN, MOUSE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HT 29 CELL LINE; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TISSUE LEVEL; UPREGULATION; ADENOMA; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELL TRANSFORMATION; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HAPLOINSUFFICIENCY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOINSUFFICIENCY; HT29 CELLS; HUMANS; INTERFERON-BETA; INTESTINAL MUCOSA; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UBIQUITINS;

EID: 84940639165     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv104     Document Type: Article

References (50)

1. Jemal, A. et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Kinzler, K.W. et al. (1996) Lessons from hereditary colorectal cancer. Cell, 87, 159-170.
3. Polakis, P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
4. Moser, A.R. et al. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324.
5. McConnell, B.B. et al. (2010) Mammalian Krüppel-like factors in health and diseases. Physiol. Rev., 90, 1337-1381.
6. Imataka, H. et al. (1992) Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J., 11, 3663-3671.
7. Mannava, S. et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib-and LBH589-induced apoptosis in multiple myeloma cells. Blood, 119, 1450-1458.
8. Simmons, C.D. et al. (2010) Response of adult mouse uterus to early disruption of estrogen receptor-alpha signaling is influenced by Krüppel-like factor 9. J. Endocrinol., 205, 147-157.
9. Ying, M. et al. (2011) Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells, 29, 20-31.
10. Pabona, J.M. et al. (2012) Krüppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis. J. Clin. Endocrinol. Metab., 97, E376-E392.
11. Zhang, Q.H. et al. (2015) Lentivirus-mediated knockdown of Krüppellike factor 9 inhibits the growth of ovarian cancer. Arch. Gynecol. Obstet., 291, 377-382.
12. Simmen, F.A. et al. (2007) Dysregulation of intestinal crypt cell proliferation and villus cell migration in mice lacking Kruppel-like factor 9. Am. J. Physiol. Gastrointest. Liver Physiol., 292, G1757-G1769.
13. Cho, Y.G. et al. (2006) Genetic alterations of the KLF6 gene in colorectal cancers. APMIS, 114, 458-464.
14. Ghaleb, A.M. et al. (2007) Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res., 67, 7147-7154.
15. McConnell, B.B. et al. (2009) Haploinsufficiency of Krüppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res., 69, 4125-4133.
16. Gaedcke, J. et al. (2010) Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer, 49, 1024-1034.
17. Kaiser, S. et al. (2007) Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol., 8, R131.
18. Kang, L. et al. (2008) Downregulation of Krüppel-like factor 9 in human colorectal cancer. Pathol. Int., 58, 334-338.
19. Sabates-Bellver, J. et al. (2007) Transcriptome profile of human colorectal adenomas. Mol. Cancer Res., 5, 1263-1275.
20. Vandesompele, J. et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3, :research0034-research0034.11.
21. Smyth, G.K. (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, Article3.
22. Morita, M. et al. (2003) Functional analysis of basic transcription element binding protein by gene targeting technology. Mol. Cell. Biol., 23, 2489-2500.
23. Simmen, R.C. et al. (2004) Subfertility, uterine hypoplasia, and partial progesterone resistance in mice lacking the Kruppel-like factor 9/basic transcription element-binding protein-1 (Bteb1) gene. J. Biol. Chem., 279, 29286-29294.
24. Coussens, L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
25. Terzić, J. et al. (2010) Inflammation and colon cancer. Gastroenterology, 138, 2101-2114.e5.
26. Boscá, L. et al. (2000) Anti-inflammatory action of type I interferons deduced from mice expressing interferon beta. Gene Ther., 7, 817-825.
27. D'Cunha, J. et al. (1996) Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. USA, 93, 211-215.
28. Andersen, J.B. et al. (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br. J. Cancer, 94, 1465-1471.
29. Bektas, N. et al. (2008) The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res., 10, R58.
30. Burks, J. et al. (2014) ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene, 33, 794-803.
31. Desai, S.D. et al. (2006) Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res., 66, 921-928.
32. Femia, A.P. et al. (2010) Gene expression profile and genomic alterations in colonic tumours induced by 1, 2-dimethylhydrazine (DMH) in rats. BMC Cancer, 10, 194.
33. Skrzypczak, M. et al. (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One, 5.
34. Moser, A.R. et al. (1992) The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol., 116, 1517-1526.
35. Li, D. et al. (2011) KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin. Cancer Res., 17, 3558-3568.
36. Slattery, M.L. et al. (2013) JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog., 52, 155-166.
37. Hanada, T. et al. (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med., 203, 1391-1397.
38. Asao, H. et al. (2000) Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation. J. Biol. Chem., 275, 867-874.
39. Simpson, J.A. et al. (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut, 59, 926-933.
40. Lee, J. et al. (2012) Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and-independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene, 31, 1242-1253.
41. Wadler, S. et al. (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res., 50, 5735-5739.
42. Ferrantini, M. et al. (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie, 89, 884-893.
43. Dunn, G.P. et al. (2005) A critical function for type I interferons in cancer immunoediting. Nat. Immunol., 6, 722-729.
44. Novakova, Z. et al. (2010) Cytokine expression and signaling in druginduced cellular senescence. Oncogene, 29, 273-284.
45. D'Cunha, J. et al. (1996) In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol., 157, 4100-4108.
46. Zhao, C. et al. (2005) Human ISG15 conjugation targets both IFNinduced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. USA, 102, 10200-10205.
47. Li, C. et al. (2014) Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget, 5, 8429-8441.
48. Tsai, Y.C. et al. (2011) Interferon-beta signaling contributes to Ras transformation. PLoS One, 6, e24291.
49. Arlt, A. et al. (2009) Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene, 28, 3983-3996.
50. Zucker, S.N. et al. (2014) Nrf2 amplifies oxidative stress via induction of Klf9. Mol. Cell, 53, 916-928.